Skip to content

Stopping and switching

What Happens When You Stop Taking a GLP-1?

Stopping a GLP-1 usually leads to substantial weight regain within a year. In a pooled analysis of 8,993 adults across 6 studies, the difference in percent body-weight change between people who stopped and people who continued averaged 17.90%.

Last checked September 14, 2026·15 sources cited·Ozempic Zepbound

Clay-style still life of an injection pen beside a bathroom scale and a discarded second pen, symbolizing stopping GLP-1 treatment.

Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.

If you stop taking Ozempic, Wegovy, Zepbound or a similar drug, the evidence is consistent: most people regain a large share of the weight they lost, and much of that regain happens within the first year. Randomized withdrawal trials such as STEP 4 and SURMOUNT-4 show that discontinuation is reliably followed by rapid weight regain, typically within one year, along with a decline in cardiometabolic benefits ^[8]. A meta-analysis of 6 studies covering 8,993 adults with overweight or obesity found that after withdrawal, the difference in percent body-weight change between the people who stopped and the people who continued was a mean of 17.90% (95% CI 14.11–21.69, P<0.0001) ^[6]. The same analysis found that body weight rose by an average of 9.11% from before to after withdrawal (95% CI 7.91–10.30) ^[6]. Those numbers are group averages, not predictions for any one person, but the direction of the finding is unusually consistent across studies ^[6]^[8].

One note on terminology: this page covers semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound) and liraglutide. Tirzepatide is not a pure GLP-1 — it is a dual GIP and GLP-1 receptor agonist — but it is often grouped with GLP-1s in the withdrawal research ^[5]^[6]^[8]. The meta-analysis above covered tirzepatide, semaglutide, liraglutide and dulaglutide, with literature searches running through December 2025 ^[6].

This page is information, not medical advice. Decisions about stopping, restarting or changing the dose of any of these drugs should be made with the prescriber who knows your history.

How much weight comes back after stopping?

The clearest pooled estimate comes from a systematic review and meta-analysis that combined 6 studies of 8,993 adults with overweight or obesity: 5,553 people discontinued their drug and 3,440 continued it ^[6]. The difference in percent body-weight change between the two groups after withdrawal was a mean of 17.90% (95% CI 14.11–21.69, P<0.0001) ^[6]. In other words, people who stopped ended up substantially heavier than the people who kept taking the drug.

The same analysis measured weight change within the discontinuation group itself, before versus after withdrawal, and found a mean increase of 9.11% of body weight (95% CI 7.91–10.30, P<0.0001) ^[6]. There was statistical heterogeneity across the included studies (P = 0.0082), which means the studies did not all agree on the exact size of the rebound, though they agreed on its direction ^[6].

A subgroup analysis within that meta-analysis found that the rebound after stopping tirzepatide was significantly larger than the rebound after stopping semaglutide ^[6]. The authors suggest that differences in the mechanism of action of these drugs may explain the differences in weight change after discontinuation ^[6].

What did the tirzepatide withdrawal trial find?

SURMOUNT-4 is the single clearest dataset on what happens when the drug stops. It was a phase 3 randomized withdrawal trial run at 70 sites in 4 countries, enrolling adults with a body mass index of 30 or higher, or 27 or higher with a weight-related complication. People with diabetes were excluded ^[4].

The trial had two phases. First, 783 participants enrolled in an open-label lead-in and received tirzepatide at the maximum tolerated dose (10 mg or 15 mg weekly) for 36 weeks. The 670 participants who completed that lead-in — mean age 48, mean weight 107.3 kg, 473 (71%) women — lost an average of 20.9% of their body weight during those 36 weeks ^[4].

At week 36, those 670 participants were randomized 1:1 — 335 continued tirzepatide and 335 switched to placebo — for a 52-week double-blind period ^[4]. The results over that year:

Measure (week 36 to week 88)	Continued tirzepatide	Switched to placebo	Difference
Mean weight change	-5.5%	+14.0%	-19.4% (95% CI -21.2% to -17.7%), P<.001 ^[4]
Maintained ≥80% of lead-in weight loss	300 participants (89.5%)	16.6%	P<.001 ^[4]
Overall weight change, week 0 to 88	-25.3%	-9.9%	— ^[4]

So the people who stopped regained an average of 14.0% of their body weight in one year, while the people who continued lost another 5.5% ^[4]. Even so, the placebo group was still 9.9% below their starting weight at week 88, because they had lost so much during the lead-in ^[4]. The trial is registered as ClinicalTrials.gov NCT04660643 ^[4].

The semaglutide equivalents are STEP 4, which compared continued weekly semaglutide against placebo for weight-loss maintenance, and the STEP 1 trial extension, which reported weight regain and cardiometabolic effects after semaglutide withdrawal ^[2]^[3]^[8]. Both found the same pattern: stopping was followed by regain, continuing maintained the loss ^[3]^[8]. A real-world follow-up of the phase 3 SURMOUNT-CN trial has also examined weight-loss maintenance after tirzepatide cessation ^[25].

How fast does the weight come back?

Across the withdrawal research, regain follows a characteristic trajectory, and a large share of it happens early — a front-loaded pattern ^[7]. Reviews describe rapid early regain followed by gradual re-equilibration ^[7].

That timing matters because the first months after stopping appear to be the critical window that influences long-term outcomes ^[7]. In SURMOUNT-4, the average regain among people who switched to placebo was 14.0% of body weight, measured over the full 52-week withdrawal period ^[4].

Why does the body regain the weight?

The regain is driven by biology, not by a lack of willpower. When the drug stops, several processes converge ^[7]:

Appetite returns once the pharmacological GLP-1 signaling is withdrawn ^[7].
Orexigenic (appetite-stimulating) hormones such as ghrelin rise in a compensatory way ^[7].
The incretin balance changes, including effects involving GIP, and there may be adaptive changes in GLP-1 receptor signaling after long exposure to the drug — though the evidence for that last mechanism is limited ^[7].
Energy expenditure stays reduced, so the body burns fewer calories at the lower weight ^[7].

Abrupt stopping creates a transient mismatch: the biological drive to regain weight is heightened at exactly the moment the drug’s appetite suppression disappears ^[7]. On top of that, the body’s homeostatic weight-defense mechanisms re-emerge after treatment stops, pushing weight back toward its pre-treatment set point ^[8].

One framing used in the medical literature is that regain after stopping is best understood as disease recurrence — obesity behaving like the chronic, relapsing condition it is — rather than as therapeutic failure by the patient or the drug ^[8].

Does blood sugar go back up after stopping?

For people with type 2 diabetes, the evidence says yes, glucose control can deteriorate. A systematic review and meta-analysis titled “Metabolic rebound after GLP-1 receptor agonist discontinuation,” published in eClinicalMedicine in 2025, examined post-discontinuation metabolic deterioration directly ^[9]. There is also a documented real-world case: when GLP-1 receptor agonists went into shortage, people with type 2 diabetes experienced deterioration of their glycemic control while off the drug ^[10].

Cardiometabolic benefits decline after discontinuation alongside the weight regain ^[8]. The STEP 1 extension reported cardiometabolic effects alongside weight regain after semaglutide withdrawal ^[2].

One safety point for anyone with diabetes: the Zepbound label warns that when the drug is used together with insulin or an insulin secretagogue, the risk of hypoglycemia increases and reducing the dose of the insulin or secretagogue may be necessary ^[5].

What happens to blood pressure, waist size and other markers?

The cardiometabolic improvements that come with weight loss tend to move with the weight. A post hoc analysis of SURMOUNT-4 published in JAMA Internal Medicine examined how cardiometabolic parameters changed according to the magnitude of weight regain after tirzepatide withdrawal ^[11]. SURMOUNT-4 itself tracked waist circumference alongside body weight in both arms ^[4]. The STEP 1 extension reported cardiometabolic effects alongside weight regain after semaglutide withdrawal ^[2]. A broader review of the causes and consequences of discontinuing GLP-1 receptor agonists or tirzepatide also covers the downstream risks ^[12].

One reassuring finding: in the pooled trial data from the meta-analysis, the incidence of cardiovascular events was not affected by withdrawal ^[6]. That is a short-term trial finding, not a long-term guarantee, but it is what the pooled data show.

Is the regained weight fat or muscle?

The evidence suggests the regained weight is disproportionately fat. A clinically underappreciated consequence of discontinuation highlighted in the medical literature is sarcopenic obesity — a pattern driven by preferential recovery of fat mass relative to lean mass ^[8].

This is one reason exercise gets attention in the withdrawal literature. A narrative review covers structured exercise during and after incretin-based pharmacotherapy discontinuation, including the mechanisms, the evidence and prescription guidance ^[13]. Resistance training in particular is discussed as a mitigation strategy for post-discontinuation regain ^[8].

Do real-world outcomes look different from trial outcomes?

Yes, and the difference is mostly about who is being measured. In the withdrawal trials, stopping means stopping — participants are randomized to placebo with no replacement therapy ^[4]^[3]. In the real world, people who stop often restart the same drug or switch to another obesity treatment, and that flattens the average regain ^[16]^[17].

An Epic Research analysis of US health records found that two years after stopping GLP-1s, most patients sustained at least some weight loss ^[16]. A clinical-practice cohort that studied obesity treatments and weight changes after discontinuation of semaglutide or tirzepatide found that many patients restart or switch treatments ^[17]. Those real-world averages are not evidence that regain is mild — they partly reflect selection and the effect of people getting back on treatment ^[16]^[17]. The trials remain the best estimate of what happens when the drug truly stops and nothing replaces it ^[4]^[6].

How many people stop, and why?

Stopping is common enough that several research teams have studied it directly. A national-level study in JAMA Network Open examined discontinuation of semaglutide therapy for obesity management ^[18]. A US claims analysis examined trends in 1-year persistence and adherence among people starting high-potency, weight loss-indicated GLP-1 receptor agonists ^[19]. A US cohort studied both discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among adults with overweight or obesity ^[20]. A real-world semaglutide obesity cohort reported effectiveness, safety and persistence across sex, BMI and prior GLP-1 use ^[21].

For context on tolerability, the most common adverse reactions reported in at least 5% of Zepbound patients are nausea, diarrhea, vomiting, constipation, abdominal pain, dyspepsia, injection site reactions, fatigue, hypersensitivity reactions, eructation, hair loss and gastroesophageal reflux disease ^[5]. On the other side of the ledger, the meta-analysis found that after withdrawal, overall adverse reactions and gastrointestinal adverse reactions decreased ^[6].

Can a lower dose or less-frequent dosing work instead of quitting?

This is an active area of research. Treatment de-escalation options under discussion include lower-dose maintenance, reduced-frequency dosing and gradual tapering, all intended to avoid the abrupt withdrawal of pharmacological support ^[7]. Recent randomized evidence suggests reduced-intensity pharmacological maintenance may attenuate weight regain compared with abrupt discontinuation ^[7].

On the label side, the FDA-approved Zepbound prescribing information states that 5 mg, 10 mg and 15 mg injected subcutaneously once weekly are all approved maintenance doses for weight reduction and long-term maintenance, and that if a maintenance dosage is not tolerated, a lower maintenance dosage may be considered ^[5]. That is what the label says; whether a lower dose is right for a specific person is a decision for that person and their prescriber.

There is also early evidence on less-frequent dosing: a case series of reduced-frequency GLP-1 dosing reported maintenance of weight, body composition and metabolic syndrome improvements, though it was small and uncontrolled ^[14]. A phase 3b trial, ATTAIN-MAINTAIN, tested oral orforglipron for maintenance of body weight reduction in a double-blind randomized design ^[24].

Is tapering an option?

It is being studied, but the honest answer is that no one knows yet whether structured tapering can successfully facilitate discontinuation; the question requires prospective evaluation ^[7].

One trial designed to answer parts of this question is REST — Recovery Effects after Semaglutide Termination — a study of the impact of semaglutide withdrawal on cardiometabolic profile and the physiology of energy balance ^[28]. It is registered as ClinicalTrials.gov NCT07294950 ^[29].

What happens if I restart after a break?

Restarting is a documented real-world pattern among US adults ^[20]. There is at least one published case report of severe gastrointestinal intolerance after a person resumed maintenance-dose semaglutide following a treatment interruption related to Ramadan fasting ^[27].

The Zepbound label carries a warning for severe gastrointestinal adverse reactions and states the drug is not recommended in patients with severe gastroparesis ^[5]. Other labeled warnings relevant to anyone restarting include acute kidney injury from volume depletion, acute gallbladder disease, acute pancreatitis, hypersensitivity reactions, and pulmonary aspiration of food or liquid during general anesthesia or deep sedation ^[5]. The label also instructs patients to tell healthcare providers about planned surgeries or procedures ^[5].

What do guidelines and drug labels say about continuing versus stopping?

The Zepbound indication is explicitly written for the long term: it is indicated, together with a reduced-calorie diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or overweight with at least one weight-related comorbid condition ^[5].

The label’s dosing schedule reflects that design. Treatment starts at 2.5 mg injected subcutaneously once weekly for 4 weeks — a dose for initiation only, not a maintenance dose — then increases in 2.5 mg increments after at least 4 weeks on the current dose, up to a maximum of 15 mg weekly ^[5]. The escalation schedule exists specifically to reduce the risk of gastrointestinal adverse reactions ^[5]. The label also contains a dedicated section on what to do about a missed dose (section 2.3) ^[5], and it states that coadministration of tirzepatide with another tirzepatide product or any GLP-1 receptor agonist is not recommended ^[5].

On the guideline side, a joint expert guidance statement from the Obesity Society, the Obesity Medicine Association and the Obesity Action Coalition, developed using the GRADE approach, addresses the pharmacological management of US adults with overweight or obesity ^[22]. The broader medical literature argues for long-term, maintenance-oriented care as the standard for a chronic condition ^[8].

A final note: none of this means a GLP-1 must be taken forever, and none of it means these drugs cure obesity — the evidence does not support that framing for any of them ^[8]. It means the trials consistently show what happens when the drug stops and nothing takes its place, and that decisions about stopping belong in a conversation with the prescriber who prescribed it.

Sources

Frequently asked questions

Will I gain all the weight back if I stop?

On average, people regain a large share but not necessarily all of it. In SURMOUNT-4, people who switched to placebo regained 14.0% of body weight in a year but were still 9.9% below their starting weight. A pooled analysis of 6 studies found a 17.90% difference in percent body-weight change between stoppers and continuers. Individual results vary.

How soon after the last shot does appetite and weight come back?

Regain is front-loaded: a large proportion happens in the early post-cessation period, described as rapid early regain followed by gradual re-equilibration. The first months after stopping are considered the critical window influencing long-term outcomes. In SURMOUNT-4, the average regain over the withdrawal year was 14.0%.

Is it safe to just stop, or do I need to taper down?

Whether structured tapering can successfully facilitate discontinuation remains unknown and needs prospective evaluation. Reduced-intensity maintenance may attenuate regain versus abrupt stopping in randomized evidence. This is a decision to make with your prescriber, not on your own.

What happens to my A1c and blood sugar if I stop and I have type 2 diabetes?

Glycemic control can deteriorate. A 2025 meta-analysis examined metabolic rebound after GLP-1 discontinuation, and a real-world shortage of these drugs led to documented deterioration of glycemic control in people with type 2 diabetes. The Zepbound label notes hypoglycemia risk when the drug is used with insulin or an insulin secretagogue.

Do blood pressure and cholesterol improvements disappear too?

Cardiometabolic benefits decline after discontinuation alongside the weight regain. A post hoc analysis of SURMOUNT-4 examined cardiometabolic changes by magnitude of regain, and the STEP 1 extension reported cardiometabolic effects after semaglutide withdrawal. Pooled trial data showed cardiovascular event incidence was not affected by withdrawal.

Is the regained weight fat or muscle?

The literature flags sarcopenic obesity as an underappreciated consequence of stopping, driven by preferential recovery of fat mass relative to lean mass. Resistance training is discussed as a mitigation strategy, and a narrative review covers structured exercise during and after discontinuation.

Can exercise or diet alone hold the weight off after stopping?

Exercise is discussed as a mitigation strategy in the withdrawal literature, and a randomized trial compared exercise, liraglutide, or both for weight-loss maintenance, with follow-up a year after all treatment stopped. But no source here shows lifestyle alone reliably prevents the regain seen in withdrawal trials.

Can I take a lower dose or dose less often instead of quitting?

The Zepbound label lists 5 mg, 10 mg and 15 mg weekly as approved maintenance doses and says a lower maintenance dosage may be considered if one is not tolerated. Reduced-intensity maintenance may attenuate regain versus abrupt discontinuation, and a small case series reported maintained results with reduced-frequency dosing. Discuss options with your prescriber.

This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.